Phylogica (ASX:PYC) Presentation, FNN Investor Event, September 2017, Sydney

19/09/2017 16:30:00

Key points

Phylogica is developing next generation intracellular biological therapeutics, including its own preclinical Myc, STAT 5 and YB1 oncology inhibitor payloads, using its proprietary best-in-class cell penetrating FPPs.

Phylogica – Key Investment Highlights

• Addressing a large unmet market need - $250Bn for biologics targeting “undruggable” targets and $110Bn cancer treatment

• Derisked investment opportunity - progressing 3 asset groups - intracellular delivery, biologic therapeutic solutions and new drug discovery

• Well validated platform technology - partnerships with Genentech, MedImmune, Pfizer, Janssen Biotech and Roche

• Strong patent position - international patents in place

• Best-in-Class compounds - leading programs FPP and iMyc are better than existing gold standard solutions

• High calibre team - attracted world-class talent from the industry and commercial sector

• Blue sky potential - extensive Phylomer library ensures a high hit rate on any target of interest 
Watch Presentation.